2-47805638-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000179.3(MSH6):c.3577G>A(p.Glu1193Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/20 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Consequence
MSH6
NM_000179.3 missense
NM_000179.3 missense
Scores
16
2
1
Clinical Significance
Conservation
PhyloP100: 9.36
Genes affected
MSH6 (HGNC:7329): (mutS homolog 6) This gene encodes a member of the DNA mismatch repair MutS family. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. Transcripts variants encoding different isoforms have been described. [provided by RefSeq, Jul 2013]
FBXO11 (HGNC:13590): (F-box protein 11) This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. It can function as an arginine methyltransferase that symmetrically dimethylates arginine residues, and it acts as an adaptor protein to mediate the neddylation of p53, which leads to the suppression of p53 function. This gene is known to be down-regulated in melanocytes from patients with vitiligo, a skin disorder that results in depigmentation. Polymorphisms in this gene are associated with chronic otitis media with effusion and recurrent otitis media (COME/ROM), a hearing loss disorder, and the knockout of the homologous mouse gene results in the deaf mouse mutant Jeff (Jf), a single gene model of otitis media. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jun 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.945
PP5
Variant 2-47805638-G-A is Pathogenic according to our data. Variant chr2-47805638-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 89422.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH6 | NM_000179.3 | c.3577G>A | p.Glu1193Lys | missense_variant | 7/10 | ENST00000234420.11 | NP_000170.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH6 | ENST00000234420.11 | c.3577G>A | p.Glu1193Lys | missense_variant | 7/10 | 1 | NM_000179.3 | ENSP00000234420 | P4 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Cov.: 33
GnomAD4 exome
Cov.:
33
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 09, 2023 | This missense variant replaces glutamic acid with lysine at codon 1193 of the MSH6 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant protein results in impaired DNA mismatch repair activity and reduced association with the MSH2 protein (PMID: 15354210). Another functional study has shown that the equivalent variant protein (p.Glu1191Lys) in mice also results in impaired DNA mismatch repair activity (PMID: 28531214). This variant has been reported in two individuals affected with endometrial cancer (PMID: 15354210, 16885385, 28531214), with microsatellite instability and/or loss of MSH6 protein expression reported in tumor samples. This variant has been reported in individuals affected with clinical features of Lynch syndrome (ClinVar SCV001492013.3). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 17, 2021 | The p.E1193K variant (also known as c.3577G>A), located in coding exon 7 of the MSH6 gene, results from a G to A substitution at nucleotide position 3577. The glutamic acid at codon 1193 is replaced by lysine, an amino acid with similar properties. This alteration has been identified in two unrelated individuals diagnosed with endometrial cancer at ages 59 and 60, respectively, whose tumors showed high microsatellite instability (MSI-H) with loss of MSH6 staining on immunohistochemistry (IHC) (Kariola R et al. Br. J. Cancer, 2004 Oct;91:1287-92; Belvederesi L et al. Fam. Cancer. 2012 Dec;11:675-80). An in vivo mismatch repair (MMR) assay demonstrated that the E1193K variant displayed complete MMR deficiency at 0%. Additionally, a co-immunoprecipitation assay showed that the E1193K protein co-precipitated much less MSH2 compared to wildtype MSH6, suggesting interference in the heterodimerization between the MSH2 and MSH6 proteins (Kariola R et al. Br. J. Cancer. 2004 Oct;91:1287-92; Hampel H et al. Cancer Res. 2006 Aug;66:7810-7). In another study, the mouse equivalent of this variant was detected in a functional genetic screen and was shown to abrogate MMR activity (Houlleberghs H et al. PLoS Genet., 2017 May;13:e1006765). Based on an internal structural assessment, this alteration destabilizes the ATPase domain (Warren JJ et al. Mol. Cell, 2007 May;26:579-92). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Lynch syndrome 5 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Aug 24, 2023 | This variant is considered pathogenic. Functional studies indicate this variant impacts protein function [PMID: 28531214, 15354210]. This variant is expected to disrupt protein structure [Myriad internal data]. This variant is strongly associated with more severe personal and family histories of cancer, typical for individuals with pathogenic variants in this gene [PMID: 27363726]. - |
Hereditary nonpolyposis colon cancer Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 04, 2023 | Variant summary: MSH6 c.3577G>A (p.Glu1193Lys) results in a conservative amino acid change located in the DNA mismatch repair protein MutS, C-terminal (IPR000432) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 249974 control chromosomes. c.3577G>A has been reported in the literature in individuals affected with endometrial cancer showing microsatellite instability and loss of MSH6 expression (Kariola_2004, Hampel_2006). These data indicate that the variant is likely associated with disease. At least two publications reports experimental evidence evaluating an impact on protein function, showing a loss of MMR activity and disruption of heterodimerisation with MSH2 (Kariola_2004, Houlleberghs_2017). Four submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 , and all classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Lynch syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 08, 2024 | This missense variant replaces glutamic acid with lysine at codon 1193 of the MSH6 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant protein results in impaired DNA mismatch repair activity and reduced association with the MSH2 protein (PMID: 15354210). Another functional study has shown that the equivalent variant protein (p.Glu1191Lys) in mice also results in impaired DNA mismatch repair activity (PMID: 28531214). This variant has been reported in two individuals affected with endometrial cancer (PMID: 15354210, 16885385, 28531214), with microsatellite instability and/or loss of MSH6 protein expression reported in tumor samples. This variant has been reported in individuals affected with clinical features of Lynch syndrome (ClinVar SCV001492013.3). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 16, 2017 | - - |
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 09, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this missense change affects MSH6 function (PMID: 15354210, 28531214). An algorithm developed specifically for the MSH6 gene suggests that this missense change is likely to be deleterious (PMID: 23621914). ClinVar contains an entry for this variant (Variation ID: 89422). This missense change has been observed in individuals with clinical features of Lynch syndrome (PMID: 15354210, 16885385; Invitae; external communication). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1193 of the MSH6 protein (p.Glu1193Lys). - |
Endometrial carcinoma Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 14, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
.;.;D;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
.;.;.;H;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
.;D;.;D;D
REVEL
Pathogenic
Sift
Pathogenic
.;D;.;D;D
Sift4G
Pathogenic
D;D;D;D;D
Polyphen
1.0
.;.;.;D;.
Vest4
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at